Gene manufacturing platforms, patient-centric formulations, contract services, packaging innovations, and sterile filling lines are in the spotlight at CPHI Milan 2026.
|Articles|November 2, 2016
- Pharmaceutical Technology-11-02-2016
- Volume 40
- Issue 11
Pharmaceutical Technology, November 2016 Issue (PDF)
Click the title above to open the Pharmaceutical Technology November 2016 issue in an interactive PDF format.
Advertisement
Articles in this issue
almost 10 years ago
The Human Factor in Inspectionsalmost 10 years ago
Application of QbD and QRM to Analytical Method Validationalmost 10 years ago
Biosimilars to Drive Modern Manufacturing Approachesalmost 10 years ago
Cleaning Validation in Continuous Manufacturingalmost 10 years ago
Lubrication in Continuous Tubular Powder Blendersalmost 10 years ago
Integrated Membrane for Single-Use Filtration Assembliesalmost 10 years ago
Dual-Shaft Mixers Provide Efficient Turnoveralmost 10 years ago
Biomolecule Separator Reduces Sample Absorptionalmost 10 years ago
Workstations Allow for Continuous Control of Cell Culture ProcessesAdvertisement
Related to this article
Ronald Piervincenzi, USP, explains why drug supply resilience needs a system approach, from procurement benchmarks to regulatory capacity building.
Episode 1, Part 3 of PharmTech AI Pulse Check covers why INTerpath-001's AI isn't ChatGPT and names pharma manufacturing's biggest AI governance gaps.
Michael Levy, senior vice president, Digital & Innovation, USP, explains the digital supply chain in a preview of his upcoming CPHI Milan panel presentation, The Next Phase of Pharma Supply Chains.
FDA approves tavapadon, first D1/D5 agonist, validating AbbVie's $8.7B Cerevel deal and an October five-strength oral tablet launch.
Richard Jaenisch weighs how FDA's new NAM rule could reshape preclinical testing and what CMC teams should do now, on Manufacturing Intelligence.
In a preview of their panel discussion at AAPS PharmSci 360 2026, Alfred Rumondor, PhD, AbbVie, and Swita Singh, PhD, Bristol Myers Squibb, discuss the implementation of risk-based approaches for CMC.
Merck licenses SciBrunch's preclinical KRAS G12D inhibitor for $2.13B, raising tech transfer and scale-up questions for oral cancer drug development.
Advertisement
Advertisement